logo
Plus   Neg
Share
Email

Twitter Acquires Newsletter Publishing Company Revue - Quick Facts

Twitter Inc. (TWTR) has acquired Revue, a service that makes it free and easy for anyone to start and publish editorial newsletters, for an undisclosed sum.

Revue will accelerate its work to help people stay informed about their interests while giving all types of writers a way to monetize their audience - whether it's through the one they built at a publication, their website, on Twitter, or elsewhere, the social media giant said in its blog post.

"Many established writers and publishers have built their brand on Twitter, amassing an audience that's hungry for the next article or perspective they Tweet. Our goal is to make it easy for them to connect with their subscribers, while also helping readers better discover writers and their content," Twitter said.

Twitter said it will continue to invest in Revue as a standalone service, and its team will remain focused on improving the ways writers create their newsletters, build their audience and get paid for their work. It is also expanding their team and hiring for key roles across engineering, design, research and data science.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
J&J Distributing has recalled various food products citing potential contamination with Listeria monocytogenes or Lm, an organism that can cause serious and sometimes fatal infections. According to the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS, around 33 pounds of ready-to-eat meat and poultry salads and wrap products have been called back. The U.S. Food and Drug Administration on Saturday authorized Johnson & Johnson's (JNJ) single-dose COVID-19 vaccine for emergency use. It is the first single-shot COVID-19 vaccine and the third COVID-19 vaccine for emergency use in the U.S. - the other two being Pfizer/BioNTech's BNT162b2 and Moderna's mRNA-1273. The U.S. Food and Drug Administration said that it will rapidly work toward finalization and issuance of an emergency use authorization of Johnson & Johnson's (JNJ) single-shot COVID-19 vaccine candidate.
Follow RTT